Scientists from three leading universities join forces to develop a new generation of medicines targeting the deadliest malaria parasite
Boca Raton, Florida, 21 July 2026 – A team of researchers from Florida Atlantic University, Brown University, and Florida International University has received a $3.8 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop an innovative class of medicines for malaria. The five-year research project aims to create new treatments that can fight drug-resistant strains of Plasmodium falciparum, the parasite responsible for the majority of malaria-related deaths worldwide.
Malaria remains one of the world’s most serious infectious diseases despite being preventable and treatable. According to the World Health Organization, the disease caused around 263 million infections and nearly 600,000 deaths in 2023, with most cases reported in sub-Saharan Africa. Young children remain the most vulnerable group, and searching for more effective medicines an urgent global health priority.
The new research focuses on a unique parasite protein known as PfGARP, which is found only on red blood cells infected by Plasmodium falciparum. Scientists previously discovered that antibodies targeting this protein can rapidly destroy malaria parasites by triggering a natural process called programmed cell death. This breakthrough has opened the door to an entirely new strategy for treating malaria, rather than relying on the same biological pathways targeted by existing drugs.
Researchers will now search for small drug molecules that can imitate the action of these protective antibodies. Using advanced high-throughput screening technologies, the team will evaluate millions of chemical compounds to identify those capable of binding to the PfGARP protein and eliminating the parasite. If successful, the approach could lead to a completely new generation of antimalarial medicines that remain effective even as resistance to current treatments continues to grow.
Florida Atlantic University will play a central role in the project by leading the identification and evaluation of promising drug candidates. Researchers at the university will use sophisticated laboratory technologies to screen and validate compounds before they move into further optimization and preclinical testing. This collaborative effort combines expertise in malaria biology, medicinal chemistry, and drug discovery to accelerate the development of safer and more effective therapies.
Drug resistance has become one of the biggest challenges in malaria control. Many existing medicines are gradually becoming less effective as the parasite evolves, increasing the need for therapies that work through entirely different mechanisms. By targeting PfGARP, scientists hope to stay ahead of resistance and provide new treatment options for millions of people living in malaria-affected regions.
Beyond developing new medicines, the project also highlights the importance of collaboration between academic institutions and public health organizations. By bringing together experts with different scientific backgrounds, the research aims to speed up discoveries that could eventually improve healthcare outcomes in countries where malaria continues to place a heavy burden on communities and healthcare systems.
If the research successfully identifies strong drug candidates, the findings could pave the way for future clinical development and provide new hope in the global fight against one of the world’s deadliest infectious diseases. As resistance continues to threaten current treatments, innovative scientific approaches such as this are expected to play a vital role in protecting millions of lives and strengthening global health security.
